Posted by Michael Wonder on 02 Mar 2016

U.S. FDA approves Gilead’s second TAF-based single tablet regimen Odefsey (emtricitabine, rilpivirine, tenofovir alafenamide) for the treatment of HIV-1 infection

1 March 2016 - Odefsey is Gilead’s second TAF-based regimen to receive FDA approval and represents the smallest pill of any single tablet regimen for the treatment of HIV.

For more details, go to: http://www.gilead.com/news/press-releases/2016/3/us-food-and-drug-administration-approves-gileads-second-tafbased-single-tablet-regimen-odefsey-emtricitabine-rilpivirine-tenofovir-alafenamide-for-the-treatment-of-hiv1-infection

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , Combination product , US , HIV infection